MEDICAL DEVICES · SERVICE DETAILS

De Novo Declaration Service

Collapse the De Novo strategy, evidentiary gaps, electronic requests and review responses for new types of devices that do not have suitable legal matching devices and may be safe and effective through general or special controls.

The absence of a suitable matching device does not automatically apply to De Novo. Whether the risk can be judged by the corresponding control management, the adequacy of the evidence and the final classification results by the FDA; The research implementation is separately recognized from the scope of documentation services.

SERVICE OVERVIEW

What does this service help with?

The search results for the intended use, technical characteristics and similar devices are collated before the proposed classification, risk and control measures are demonstrated and the request documents are organized to match the evidence. An assessment of the path, a list of gaps, a structure of information, the submission of documents and a record of responses could be provided as agreed.

WHO MAY NEED IT

Who should consider this service?

Enterprises that develop new medical devices that do not recognize suitable legitimate matching devices and that are to evaluate the cross-Class I or Clas II path. High-risk and inadequately controlled devices, both general and special, should be evaluated separately.

SCOPE & APPROACH

What can De Novo’s support include?

Classification validation, technical evidence, research execution and communication with the FDA agree separately that the template will not be completed as a complete declaration.

01

ANALYSIS OF APPLICATION AND THE SAME MATERIAL

Reconnaissance of objects of use, technology and legal comparison, assessment of direct de Novo or existing NSE follow-up paths, recording the proposed classification basis and the matter to be confirmed.

02

Evidence of risk, benefits and control measures

Collating identifies hazards, risks and benefits, explaining why general or general and special controls are sufficient, and clearly supporting the evidence required to justify them.

03

Non-clinical versus applicable clinical evidence planning

(b) To develop a gap list by product-checking of applicable information such as performance, software, biocompatibility, sterilisation and clinical evidence needs; Tests and research implementation are listed separately.

04

Advance communication information collaboration

Pre-Submission questions, background and information kits prepared as required and agreed upon, and feedback and implications for the follow-up plan; Prior feedback is not a substitute for formal decisions.

05

eSTAR Request and Submission Check

The current application of eSTAR requires the organization of administrative, product, evidentiary and labelling documents, checking attachment consistency, authorization and cost, and collaborating to submit and maintain records.

06

Follow-up to the review response and the decision

Collation of FDA questions, references to evidence and responses, supplemented by agreed collaborations; When granted, the interfaces of classification control, labelling and registration for listing are clearly applied.

GET READY

The product innovation points and the existing evidence catalogue are provided first.

The initial evaluation may be preceded by a non-confidential summary; The study and the detailed technical information are handed over in accordance with the authorization and confidentiality arrangements.

  • Product description, intended use, adaptive, user and use environment
  • Retrieval of the same product, comparison device analysis and FDA communication already available
  • Proposed classification, risk benefit analysis and general and special control recommendations
  • Directory of applicable reports on performance, software, sterilisation, biocompatibility, etc.
  • Clinical evidence and plans, label instructions and technical information to be added
  • Subject of application, project manager, information authorization and target plan
HOW TO START

From initial review to engagement

STEP 01

Assessment of pathways and available evidence

Check products and similar devices to identify risk control and path to be confirmed.

STEP 02

Building gaps and research collaboration schemes

Identify responsibilities, milestones and costs for documentation, test studies and forward communication.

STEP 03

Organizational requests and reconciliation of submissions

Prepare information, align labels and evidence according to the current template, complete review and apply submission.

STEP 04

Follow-up questions and referral decisions

Collaborative response, preservation of versions and decisions, clear follow-up control and maintenance.

The absence of a suitable matching device does not automatically apply to De Novo. Whether the risk can be judged by the corresponding control management, the adequacy of the evidence and the final classification results by the FDA; The research implementation is separately recognized from the scope of documentation services.

TIMING & FEES

Timing and fees

Information reviewed:Fee period: FY 2027, October 1, 2026 through September 30, 2027. For other charges, use the FDA rules as of the review date.

Timing and preparation

Document preparation

Queues by path, forward communication, non-clinical and applicable clinical research, document preparation. The degree of innovation, control measures and evidentiary gaps affect the calendar plan, and research and business response times should be listed separately.

FDA processing

De Novo of MDUFA V decided to target 150 FDA review days with the applicable percentage of performance determined on an annual and conditional basis; Not all requests for completion commitments. The suspension of the supplementary information and the enterprise response do not amount to the FDA being reviewed.

Fee breakdown

FDA fees

FY 2027 Standard application fee US$191,020; The applicable small business has been identified as US$ 47,755. Tests, research and other submission costs are shown separately.

Service fees

Bids by path assessment, control validation, forward communication, eSTAR document preparation, submission and response cycle, indicating whether the study was carried out and the maintenance was authorized to include them.

Other possible costs

Applied performance, software, biocompatibility, electrical safety, sterilisation and clinical testing studies, translation and other third-party costs are listed separately and are not included in the FDA application fee.

OFFICIAL SOURCES

FDA Official Basis and Check Date

Data check: 2026-11-06. Specific application conditions, formats and costs should be identified in conjunction with the current FDA rules and project facts.

START WITH YOUR PRODUCT

Starting with the analysis of the intended use, technical characteristics and similar devices.

Provide a summary of the product, a catalogue of test studies already available, and path questions, confirming De Novo’s applicability and evidence readiness.